Milani, Hani
Tajalli, Saleheh
Behrouzi, Kamran
Homan, Nakisa
Zamaniashtiani, Fateme
Vafaee, Ali
Vahedi, Zahra
Khalesi, Nasrin
Article History
Received: 1 April 2023
Accepted: 20 June 2024
First Online: 2 August 2024
Declarations
:
: In all steps carried out in this study, the principles of the Declaration of Helsinki. The intervention substances were administered with informed consent from the newborns’ parents before blinding. The infant’s caretaker was properly informed about enrolling in the study and their informed consent was taken. They were free to withdraw from the study in any step of the study and for any reason or for no reason at all. All patients’ information was held confidential, was not made accessible to any person or organization and was reported only in aggregate. Ethics approval for the study was obtained from the institutional review board of Iran University of Medical Sciences according to Helsinki declaration (ID; IR. IUMS. REC 1395.9411403002) and has been registered at Iranian Registry of Clinical Trials (Registration date: 2017-10-12, identifier: IRCT2017053034223N1, ).
: Not applicable.
: The authors declare no competing interests.